Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | NAPSR News: New technique brings us closer to HIV and hepatitis C vaccinesPlans for a new type of DNA vaccine to protect against the deadly HIV and Hepatitis C viruses have taken an important step forward, with University of Adelaide researchers applying for a patent based on groundbreaking new research.
By: NAPSRx While pre-clinical research into this vaccination technique is still underway, he's now searching for a commercial partner to help take it to the next stage. Professor Gowans' work has focused on utilizing the so-called "accessory" or "messenger" cells in the immune system, called dendritic cells, to activate an immune response. These are a type of white blood cell that play a key role during infection and vaccination. "There's been a lot of work done in the past to target the dendritic cells, but this has never been effective until now," Professor Gowans says. "What we've done is incredibly simple, but often the simple things are the best approach. We're not targeting the dendritic cells directly – instead, we've found an indirect way of getting them to do what we want." Professor Gowans and his team have achieved this by including a protein that causes a small amount of cell death at the point of vaccination. "The dead cells are important because they set off danger signals to the body's immune response. This results in inflammation, and the dendritic cells become activated. Those cells then create an environment in which the vaccination can be successful," Using a micro-needle device provided by United States company FluGen Inc., the researchers can puncture the skin to a depth of 1.5mm, delivering the vaccination directly into the skin. "We chose the skin instead of the muscle tissue, which is more common for DNA vaccines, because the skin has a high concentration of dendritic cells," Professor Gowans says. Because the technique has the potential to translate to other, more common viruses in addition to the devastating HIV and Hepatitis C, the project attracted seed funding from The Hospital Research Foundation, and additional funding from the National Health and Medical Research Council (NHMRC). The research is still in the pre-clinical phase, with a patient study due next year. "This technique has worked much better than I anticipated," NOW IS THE TIME TO ENTER INTO THIS WONDERFUL FIELD. With such industry leaders posting gains in profitability, they will need both certified and qualified individuals to sell their product. When industry leaders look for new candidates for entry level positions, they look toward individuals that are industry trained. Reason being that they are looking for people that have the background to sell their product both proficiently and efficiantly. CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!- Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. The CNPR® represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions. The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community. Individuals that are interested in becoming a Certified National Pharmaceutical Representative( 800-284-1060 www.napsronline.com End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|